Table 1 The baseline characteristics of all eligible trials in this meta-analysis

From: The impact of angiotensin receptor blockers on arterial stiffness: a meta-analysis

Author (year)

Ethnicity

Status

PWV type

Design

Masking

ARB type

Drugs in controls

Treatment

Control

Follow-up (months)

Mahmud and Feely8

Caucasian

Hypertension

cfPWV

Crossover

Open

Valsartan

ACEI

12

12

4

Mahmud and Feely8

Caucasian

Hypertension

cfPWV

Crossover

Double

Losartan

Diuretics

11

11

4

Asmar et al.26

Caucasian

Hypertension

cfPWV

Crossover

Double

Telmisartan

Placebo

20

20

3

Suzuki et al.36

East Asian

Others

baPWV

Parallel

Double

Valsartan

Placebo

14

10

48

Takami and Shigemasa37

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

CCB

20

16

12

Takami and Shigemasa37

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

CCB

20

20

12

Takami and Shigemasa37

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

ACEI

20

20

12

Munakata et al.32

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

CCB

21

20

12

Anan25

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

ACEI

10

11

40

Ichihara et al.27

East Asian

Hypertension

baPWV

Parallel

Open

Losartan

ACEI

22

21

48

Ichihara et al.27

East Asian

Hypertension

baPWV

Parallel

Open

Losartan

Placebo

22

21

48

Ichihara et al.28

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

CCB

50

50

48

Rajagopalan et al.34

Caucasian

Healthy

cfPWV

Crossover

Double

Valsartan

Placebo

33

33

13

Morimoto et al.31

East Asian

Hypertension

baPWV

Parallel

Open

Telmisartan

CCB

21

22

24

Zhao50

East Asian

Hypertension

cfPWV

Parallel

NA

Valsartan

Placebo

20

20

12

Rehman et al.35

Caucasian

Hypertension

cfPWV

Parallel

Double

Losartan

ACEI

19

20

12

Nakayama et al.33

East Asian

Hypertension

baPWV

Parallel

Double

Telmisartan

Beraprost sodium

20

20

12

Kosch et al.29

Caucasian

Hypertension

cfPWV

Parallel

Double

Valsartan

Beta blocker

25

27

12

Zheng and Lin51

East Asian

Hypertension

baPWV

Parallel

Open

Valsartan

Diuretics

21

18

12

Zheng and Lin51

East Asian

Hypertension

baPWV

Parallel

Open

Valsartan

Beta blocker

21

20

12

Zheng and Lin51

East Asian

Hypertension

baPWV

Parallel

Open

Valsartan

CCB

21

24

12

Zheng and Lin51

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

ACEI

21

22

12

Nakamura et al.12

East Asian

Hypertension

baPWV

Parallel

Open

Telmisartan

CCB

15

15

48

Ishii et al.17

East Asian

Hypertension

baPWV

Parallel

Open

Candesartan

CCB

11

11

12

Shigenaga et al.22

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

Non-RAS

15

15

24

Shigenaga et al.22

East Asian

Hypertension

baPWV

Parallel

NA

Candesartan

Non-RAS

15

15

24

Ruan et al.46

East Asian

heart failure

baPWV

Parallel

Open

Irbesartan

Non-RAS

25

22

12

Li et al.43

East Asian

Hypertension

baPWV

Parallel

Open

Telmisartan

ACEI

34

34

12

Li et al.43

East Asian

Hypertension

baPWV

Parallel

Open

Telmisartan

CCB

34

34

12

Mitsuhashi et al.11

East Asian

Hypertension

baPWV

Parallel

Open

Losartan

Non-RAS

20

20

48

Long and Liu45

East Asian

Others

baPWV

Parallel

NA

Valsartan

CCB

35

40

24

Li and Wang44

East Asian

Hypertension

baPWV

Parallel

Open

Telmisartan

CCB

48

45

12

Li and Wang44

East Asian

Hypertension

baPWV

Parallel

Open

Telmisartan

Diuretics

48

42

12

Ruan et al.47

East Asian

Hypertension

baPWV

Parallel

Open

Candesartan

Non-RAS

23

19

12

Han et al.19

East Asian

Others

baPWV

Parallel

Open

Valsartan

Statins

57

57

24

Lunder et al.21

Caucasian

Healthy

cfPWV

Parallel

Double

Valsartan

Placebo

20

20

4

Wu et al.48

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

CCB

48

50

2

Wu et al.48

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

ACEI

48

49

2

He et al.39

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

CCB

44

44

12

Feng38

East Asian

Hypertension

baPWV

Parallel

Open

Telmisartan

CCB

44

49

12

Tomiyama et al.20

East Asian

Hypertension

baPWV

Parallel

Open

Candesartan

CCB

56

57

32

Hayoz et al.10

Caucasian

Hypertension

baPWV

Parallel

Double

Valsartan

CCB

63

62

38

Spanos et al.13

Caucasian

Hypertension

cfPWV

Parallel

NA

Valsartan

Renin inhibitor

14

15

24

Yang et al.49

East Asian

Hypertension

baPWV

Parallel

NA

Valsartan

Diuretics

42

40

24

Kong et al.41

East Asian

Hypertension

baPWV

Parallel

Open

Irbesartan

ACEI

34

34

12

Kong et al.41

East Asian

Hypertension

baPWV

Parallel

Open

Irbesartan

CCB

34

34

12

Li and Ma42

East Asian

Hypertension

baPWV

Parallel

Open

Telmisartan

CCB

33

34

24

Huang et al.40

East Asian

Hypertension

baPWV

Parallel

Double

Losartan

Eplerenone

40

37

12

Kim et al.11

East Asian

Hypertension

cfPWV

Parallel

Open

Losartan

Beta blocker

88

94

24

Ihm et al.24

East Asian

Hypertension

cfPWV

Parallel

Open

Losartan

CCB

99

101

24

Agnoletti et al.23

Caucasian

Hypertension

cfPWV

Parallel

Open

Candesartan

CCB

33

33

12

Agnoletti et al.23

Caucasian

Hypertension

cfPWV

Parallel

Open

Candesartan

Diuretics

33

44

12

Agnoletti et al.23

Caucasian

Hypertension

cfPWV

Parallel

Open

Candesartan

Placebo

33

35

12

  1. Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; baPWV and cfPWV, brachial-ankle and carotid-femoral pulse wave velocity; CCB, calcium channel blocker; NA, not available; RAS, renin–angiotensin system.